Stock ADAP ADAPTIMMUNE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Real-time Estimate Cboe BZX
Other stock markets
 09:54:11 30/04/2024 pm IST 		5-day change 1st Jan Change
1.175 USD +2.17% Intraday chart for Adaptimmune Therapeutics plc +3.27% +48.46%
29/04 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
24/04 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Barclays Adjusts Adaptimmune Therapeutics Price Target to $1 From $2, Maintains Underweight Rating
MT
EF Hutton Initiates Adaptimmune Therapeutics at Buy With $10 Price Target
MT
Guggenheim Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $5
MT
Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $3 From $1.50, Maintains Equal-Weight Rating
MT
Mizuho Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $9
MT
SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $3 from $7, Keeps Market Perform Rating
MT
Barclays Cuts Price Target for Adaptimmune Therapeutics to $2 From $4, Maintains Underweight Rating
MT
ADAPTIMMUNE THERAPEUTICS : Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $7 From $6, Maintains Equal-Weight Rating
MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics PT to $7 From $6, Maintains Market Perform Rating
MT
Adaptimmune Therapeutics plc Announces Clinical Responses Across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation Surpass Trial
CI
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $6 from $5, Keeps Market Perform Rating
MT
ADAPTIMMUNE THERAPEUTICS : Barclays Starts Adaptimmune Therapeutics at Underweight With $4 Price Target
MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerung Adjusts Adaptimmune Therapeutics PT to $6 From $10, Maintains Market Perform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADAP Stock
  4. News Adaptimmune Therapeutics plc
  5. Analyst Reco.